SCHEMBL1003360

SCHEMBL1003360

C[C@](NC(=O)C(F)F)(c1ccc(F)c(F)c1)c1ccc(CN2CCC(c3ccc(F)nc3)CC2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.40
ADRA1A P35348 3/20 0.40
PRKAA2 P54646 8/20 0.39
PIK3CA P42336 7/20 0.39
PRKAB2 O43741 2/20 0.38
PRKAG1 P54619 2/20 0.38
PRKAA1 Q13131 2/20 0.38
PRKAG3 Q9UGI9 2/20 0.38
PRKAG2 Q9UGJ0 2/20 0.38
PRKAB1 Q9Y478 2/20 0.38
KCNH2 Q12809 2/20 0.37
MCHR1 Q99705 1/20 0.37
DRD3 P35462 1/20 0.36
PPARD Q03181 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
CCR5 P51681 2/20 0.35
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1003361 1.00 DRD2 (0.40) DRD2ADRA1APRKAA2PIK3CAPRKAB2
SCHEMBL1001547 0.83 JAK2 (0.37) DRD2ADRA1APRKAA2PIK3CAPRKAB2
SCHEMBL1001548 0.83 JAK2 (0.37) DRD2ADRA1APRKAA2PIK3CAPRKAB2
SCHEMBL1004296 0.82 KCNH2 (0.40) DRD2ADRA1APRKAA2PIK3CAPRKAB2
SCHEMBL1003096 0.73 DRD2 (0.39) DRD2ADRA1AKCNH2MCHR1JAK2
SCHEMBL1003094 0.73 DRD2 (0.39) DRD2ADRA1AKCNH2MCHR1JAK2
SCHEMBL1001840 0.73 MCHR1 (0.45) DRD2ADRA1APRKAA2PRKAB2PRKAG1
SCHEMBL1003710 0.73 DRD2 (0.42) DRD2ADRA1AKCNH2MCHR1CCR5
SCHEMBL1003708 0.73 DRD2 (0.42) DRD2ADRA1AKCNH2MCHR1CCR5
SCHEMBL1002976 0.71 DRD2 (0.38) DRD2ADRA1APRKAA2PIK3CAPRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015198-A1 DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM BANYU PHARMACEUTICAL CO., INC. 2011-01-20 US claimed
EP-2272841-A1 DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR Banyu Pharmaceutical Co., Ltd. (JP) 2011-01-12 EP claimed
US-20110015198-A1 DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM BANYU PHARMACEUTICAL CO., INC. 2011-01-20 US disclosed
EP-2272841-A1 DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR Banyu Pharmaceutical Co., Ltd. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015198-A1 DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM MC1R, MCHR2, MCHR1 DRD2 164/4885ADRA1A 38/4885PRKAA2 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.